Related Experiment Video
Updated: Aug 17, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Treatment of an acquired coagulopathy with recombinant activated factor VII in a damage-control patient
John B Holcomb1, Keith Hoots, Fredrick A Moore
1Department of Trauma and Critical Care, University of Texas Health Science Center, Houston, TX 77030, USA.
Abstract:
Recombinant activated factor VII is commonly used for the treatment of hemophiliac patients with inhibitors and has been studied for use in trauma. We report the use of recombinant activated factor VII for a male patient who was injured in a motor vehicle accident. We also summarize the animal studies and clinical trials that have been reported.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
